| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0fc19d8d6ba9ad5c1fa5770341472b56 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0078
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M13-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2001-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cfd870e6fd9f612d45ec6b4af001f85b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c8e5026cb11140bbcaa5ece38842e24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15c146360eb541f775261bcc40182c6b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aba6208966e70c9ec70a8ba5784a5b0c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44d2ce4c61d44e31bdc5910ea1305f9d |
| publicationDate |
2002-01-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2415498-A1 |
| titleOfInvention |
Macrolide formulations for inhalation and methods of treatment of endobronchial infections |
| abstract |
Macrolide formulations, such as an erythromycylamine formulation, for delive ry by aerosolization are described. The concentrated erythromycylamine formulations contain an amount of erythromycylamine effective to treat infections caused by susceptible bacteria. Unit dose devices having a container containing a formulation of the macrolide antibiotic in a physiologically acceptable carrier are also described. Methods for treatment of pulmonary infections by a formulation (liquid solution, suspension, or dr y powder) delivered as an aerosol having mass median aerodynamic diameter predominantly between 1 to 5 .mu.m are also described. |
| priorityDate |
2000-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |